The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Apr. 26, 2016

Filed:

Jul. 15, 2008
Applicant:

Frederick H. Hausheer, Boerne, TX (US);

Inventor:

Frederick H. Hausheer, Boerne, TX (US);

Assignee:

BioNumerik Pharmaceuticals, Inc., San Antonio, TX (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/095 (2006.01); A61K 33/24 (2006.01); A61K 31/105 (2006.01); A61K 31/282 (2006.01); A61K 31/337 (2006.01); A61K 31/437 (2006.01); A61K 31/505 (2006.01); A61K 31/704 (2006.01); A61K 31/7064 (2006.01); A61K 31/7076 (2006.01); A61K 38/05 (2006.01); A61K 38/06 (2006.01); A61K 45/06 (2006.01); G01N 33/574 (2006.01);
U.S. Cl.
CPC ...
A61K 33/24 (2013.01); A61K 31/095 (2013.01); A61K 31/105 (2013.01); A61K 31/282 (2013.01); A61K 31/337 (2013.01); A61K 31/437 (2013.01); A61K 31/505 (2013.01); A61K 31/704 (2013.01); A61K 31/7064 (2013.01); A61K 31/7076 (2013.01); A61K 38/05 (2013.01); A61K 38/06 (2013.01); A61K 45/06 (2013.01); G01N 33/57407 (2013.01); G01N 2333/90212 (2013.01);
Abstract

The present invention discloses and claims compositions, methods of treatment, and kits which cause an increase in time of survival in cancer patients, wherein the cancer either: (i) overexpresses thioredoxin or glutaredoxin and/or (ii) exhibits evidence of thioredoxin- or glutaredoxin-mediated resistance to one or more chemotherapeutic interventions. The present invention also discloses and claims methods and kits for the administration of said compositions to properly treat cancer patients. Additionally, the present invention discloses and claims methods and kits for quantitatively determining the level of expression of thioredoxin or glutaredoxin in the cancer cells of a cancer patient, methods of using those determined levels in the initial diagnosis and/or planning of subsequent treatment methodologies for said cancer patient, as well as ascertaining the potential growth 'aggressiveness' of the particular cancer and treatment responsiveness of the particular type of cancer. Further, the present invention discloses and claims novel pharmaceutical compositions, methods, and kits used for the treatment of patients with medical conditions and disease where there is the overexpression of thioredoxin and/or glutaredoxin, and wherein this overexpression is associated with deleterious physiological effects in the patients.


Find Patent Forward Citations

Loading…